Assistant Clinical Professor of Psychiatry, Brown University School of Medicine
Dr. Posternak has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity. The author has disclosed that triidothyronine and methylphenidate have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved usage of these drugs.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
